Artemis Therapeutics Receives Orphan Drug Designation From U.S. Food And Drug Administration For Artemisone For The Treatment Of Malaria

NEW YORK, Nov. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Artemis Therapeutics, Inc. (OTCQB: ATMS), ("Artemis" or the "Company"), a pharmaceutical company developing new therapies for the treatment of life-threatening infecti... Biopharmaceuticals, FDA Artemis Therapeutics, Artemisone, malaria
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news